Analysis ID |
159 |
Analysis location |
“GENESIS” Centre for Medical Genetics |
Diagnosed illness |
Medullary thyroid carcinoma, MEN2A, MEN2B |
OMIM |
#155240; #171400;#162300 |
Clinical information |
Medullary thyroid carcinoma comprises less than 10% of all thyroid cancers. This specific type has significant diagnostic importance due to its aggressive nature and close association with multiple endocrine neoplasia syndromes. Approximately 10% to 20% cases affected by medullary thyroid carcinoma are familial. In the majority of cases nodal metastases are present at the moment of diagnosis. |
Type of analysis |
Molecular |
Type of biological material |
5 ml of peripheral blood collected in an ETDA tube; DNA sample |
Analyzed genes |
RET |
Analysis description |
Sequencing of 6 exons of the RET gene |
Analysis indication |
All patients affected by medullary thyroid carcinoma should be tested |
Analysis time |
3 - 4 weeks |
Refund |
No |
CGM laboratory name |
Laboratory for Molecular Genetics and Oncology |